A61K 47/6863
The tumour determinant being from stomach or intestines cancer cell
Official title: {the tumour determinant being from stomach or intestines cancer cell}
A61K47/6863 (The tumour determinant being from stomach or intestines cancer cell) appears on 260 US grants and 426 published applications in this corpus.
Search patents in A61K- Granted patents
- 260
- Published applications
- 426
- Assignees
- 163
- Inventors
- 759
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 4 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 2 | 6 |
| 2006 | 2 | 4 |
| 2007 | 4 | 4 |
| 2008 | 7 | 7 |
| 2009 | 3 | 7 |
| 2010 | 7 | 8 |
| 2011 | 1 | 6 |
| 2012 | 4 | 6 |
| 2013 | 7 | 14 |
| 2014 | 9 | 17 |
| 2015 | 13 | 18 |
| 2016 | 24 | 38 |
| 2017 | 21 | 38 |
| 2018 | 12 | 34 |
| 2019 | 30 | 27 |
| 2020 | 22 | 22 |
| 2021 | 21 | 27 |
| 2022 | 10 | 30 |
| 2023 | 13 | 23 |
| 2024 | 13 | 24 |
| 2025 | 22 | 30 |
| 2026 | 4 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compounds capable of binding to proteins and conjugates obtained from these compounds8 Sep 2026US 12,728,170 B2Mc Saf
- Compositions and methods for improving tumor penetration of tumor specific antibodies19 May 2026US 12,630,649 B2The Research Foundation for The State University of New York
- Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy14 Apr 2026US 12,599,676 B2Imperial College Innovations Limited
- Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof10 Feb 2026US 12,545,735 B2Regeneron Pharmaceuticals, Inc.
- Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers30 Dec 2025US 12,508,321 B2Hangzhou Dac Biotech Co., Ltd.
- Anti-HER2 Antibodies and Immunoconjugates1 Oct 2026US 2026/0297214 A1Genentech, Inc.
- Compositions and methods for improving tumor penetration of tumor specific antibodies10 Sep 2026US 2026/0265413 A1The Research Foundation for The State University of New York
- Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy27 Aug 2026US 2026/0248948 A1Imperial College Innovations Limited
- Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof20 Aug 2026US 2026/0242515 A1Duality Biologics (Shanghai) Co., Ltd.
- Antibody-drug conjugate targeting claudin18.230 Jul 2026US 2026/0216353 A1Fortvita Biologics (Singapore) Pte. Ltd.
Most cited
By later US patents
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Remodeling and glycoconjugation of peptides91US 7,138,371 B2Neose Technologies, Inc. · 2006
- Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer87US 9,233,125 B2University of Maryland, Baltimore · 2016
- Hydrophilic self-immolative linkers and conjugates thereof79US 9,089,614 B2AbGenomics International Inc. · 2015
- Camptothecin-binding moiety conjugates76US 8,268,317 B2Immunomedics, Inc. · 2012